Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN – Get a rating) received an average “Buy” recommendation from the eleven research firms that currently cover the company, Market Beat Ratings reports. Two analysts rated the stock with a hold rating and eight gave the company a buy rating. The 12-month average target price among brokerages that have covered the stock over the past year is $152.60.
Several research companies have recently published reports on BHVN. HC Wainwright reiterated a “buy” rating and set a target price of $160.00 on Biohaven Pharmaceutical shares in a Friday, January 7 research report. Mizuho raised its price target on Biohaven Pharmaceutical from $144.00 to $154.00 and gave the company a “buy” rating in a Thursday, March 3 research note. Finally, Morgan Stanley lowered its price target on Biohaven Pharmaceutical from $148.00 to $146.00 and set an “equal weight” rating for the company in a Wednesday, April 6 research note.
Major investors have recently changed their stakes in the company. National Bank of Canada FI acquired a new stake in Biohaven Pharmaceutical during the fourth quarter valued at approximately $28,000. Elkhorn Partners Limited Partnership acquired a new position in shares of Biohaven Pharmaceutical during the fourth quarter worth approximately $48,000. Harbor Investment Advisory LLC increased its position in Biohaven Pharmaceutical shares by 25.4% during the fourth quarter. Harbor Investment Advisory LLC now owns 587 shares of the company worth $81,000 after buying 119 additional shares in the last quarter. Montag A & Associates Inc. acquired a new position in shares of Biohaven Pharmaceutical during the third quarter worth approximately $96,000. Finally, the Canada Pension Plan Investment Board acquired a new position in shares of Biohaven Pharmaceutical during the fourth quarter worth approximately $104,000. Institutional investors hold 88.03% of the company’s shares.
NYSE: BHVN opened at $90.25 on Friday. Biohaven Pharmaceutical has a 12-month low of $65.24 and a 12-month high of $151.51. The stock has a 50-day moving average price of $112.37 and a 200-day moving average price of $121.51. The stock has a market capitalization of $6.37 billion, a P/E ratio of -6.90 and a beta of 1.20.
Biohaven Pharmaceutical (NYSE: BHVN – Get a rating) last released its results on Friday, February 25. The company reported ($3.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.07) by ($0.94). The company posted revenue of $190.01 million in the quarter, compared to $175.54 million expected by analysts. During the same period of the previous year, the company achieved EPS ($3.62). The company’s quarterly revenue increased by 441.1% compared to the same quarter last year. Research analysts predict that Biohaven Pharmaceutical will post an EPS of -8.51 for the current year.
About Biohaven Pharmaceutical (Get a rating)
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, is developing product candidates targeting neurological and neuropsychiatric diseases and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as the development of Rimegepant for the preventive treatment of migraine; Zavegepant which is in Phase III clinical trials for the acute and preventive treatment of migraine, as well as for respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications.
Get news and reviews for Biohaven Pharmaceutical Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com’s free daily email newsletter.